. The GAA repeat shows somatic instability, with progressive expansion throughout life, particularly in the cerebellum and dorsal root ganglia (DRG) (3) (4) (5) . The effect of the GAA expansion mutation is to reduce the expression of frataxin (6), a mitochondrial protein that acts as an iron chaperone in iron-sulphur cluster and heme biosynthesis (7-9). Frataxin insufficiency leads to oxidative stress, mitochondrial iron accumulation and resultant cell death, with the primary site of pathology being in the large sensory neurons of the DRG and the dentate nucleus of the cerebellum (10). The outcome is progressive spinocerebellar neurodegeneration, causing symptoms of ataxia, dysarthria, muscle weakness, and sensory loss, together with cardiomyopathy, and diabetes. At present there is no effective treatment for FRDA, and affected individuals generally die in early adulthood from the associated heart disease.
Preclinical and clinical trials using antioxidants and iron chelators have demonstrated some limited success in alleviating FRDA heart pathology (11-16).
However, a more effective overall therapeutic strategy may be to target the immediate effects of the GAA repeat expansion mutation to restore normal levels of frataxin expression. The exact mechanism by which the GAA repeat F o r P e e r R e v i e w 4 expansion leads to decreased frataxin expression is unknown, but several models have been put forward. Firstly, it has been suggested that the GAA repeat expansion may adopt abnormal DNA or DNA/RNA hybrid structures that interfere with FXN gene transcription (17) (18) (19) (20) . Secondly, there is evidence that GAA repeat expansions produce a heterochromatin-mediated gene silencing effect (21) . Epigenetic mechanisms, such as DNA methylation and the associated deacetylation and methylation of histones are known to affect gene expression by chromatin remodelling (22) , and these epigenetic changes are likely to underpin any GAA repeat-induced heterochromatin-mediated gene silencing effects. In support of this hypothesis, research has recently shown increased DNA methylation of three specific CpG sites immediately upstream of the expanded GAA repeat sequence in FRDA patient lymphoblastoid cell lines and primary lymphocytes, and one of the three CpG sites was identified as an important enhancer of frataxin expression (23) . Other studies have identified specific histone modifications that are associated with gene silencing within the GAA repeat expansion-flanking regions of the FXN intron 1 sequence in FRDA lymphoblastoid cell lines and primary lymphocytes (23, 24) . These changes include deacetylation of histone H3 and H4 lysine residues and increased di-and trimethylation of H3K9. Based on the hypothesis that the acetylation state of the core histones is responsible for gene silencing, novel histone deacetylase (HDAC) inhibitor compounds have been developed and have been shown to increase FXN transcription in FRDA lymphoblastoid cells and primary lymphocytes (24) . These previous epigenetic studies have provided valuable insights into the possible mechanism of GAA-induced transcription inhibition, but they do not address the issue of whether such epigenetic changes are actually present in the most clinically relevant FRDA tissues. Therefore, we decided to investigate epigenetic profiles of the FXN gene in FRDA patient autopsy brain and heart tissue. By bisulfite sequencing and ChIP analysis we now report changes in DNA methylation and histone modifications that are consistent with inhibition of FXN transcription. With a view to future epigenetic-based FRDA therapies, we also investigated the FXN epigenetic profiles within brain and heart tissue from our Y47, YG8 and YG22 FRDA YAC transgenic mouse models (25-27). We find that the GAA repeat expansion-containing FRDA mouse models (YG8 and YG22) exhibit comparable epigenetic changes to those detected in FRDA patient tissue.
Therefore, these are excellent FRDA mouse models in which to investigate the therapeutic effects of epigenetically-acting compounds, such as novel HDAC inhibitors or DNA methylation inhibitors. (23) . This same study also reported a lack of any DNA methylation in the promoter region of either FRDA or unaffected cells.
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However, cultured cells are known to often develop non-physiological DNA methylation profiles. Furthermore, FRDA is a systemic disorder that is known to have differentially affected tissues and cell types. Therefore, we chose to investigate the DNA methylation status in two of the primary affected tissues in FRDA, namely brain and heart. We obtained brain and heart autopsy tissues from an FRDA patient (GAA repeat sizes of 750 and 650) and an unaffected individual, and we firstly determined the FXN transcription levels of the samples by quantitative RT-PCR. The FRDA brain and heart samples showed 12% and 67% FXN expression, respectively, compared with the unaffected samples ( Fig.   1 ). We then analysed the DNA methylation status of the samples by performing bisulfite sequence analysis of three regions of the FXN gene: (i) a 475bp sequence that encompasses part of the FXN promoter, exon 1 and start of intron 1, containing 59 CpG sites; (ii) a 286bp sequence upstream of the GAA repeat, containing 8 CpG sites, and (iii) a 275bp sequence downstream of the GAA repeat, containing 12 CpG sites (Fig. 2) . A comparison of the bisulfite sequences from the FRDA patient and control brain and heart tissues reveals a certain degree of DNA methylation in all 8 of the upstream GAA CpG sites ( Fig. 3C and   D ) and all 12 of the downstream GAA CpG sites ( Fig. 3E and F) . However, the data show a consistent shift in the DNA methylation pattern around the GAA repeat in both tissue types. The FRDA upstream GAA CpG sites are comparatively hypermethylated, whereas the FRDA downstream GAA CpG sites (Fig. 3C-F) . The greatest increase in DNA methylation within the upstream GAA region is seen at CpG site 4. Significantly increased DNA methylation is also seen at CpG sites 5 and 6, the latter of which corresponds to the previously described E-box enhancer element (23) . We observed 100% methylation at CpG site 6 in FRDA brain tissue (FXN mRNA level of 12%, Fig.1 ) compared with 80% methylation in heart tissue (FXN mRNA level of 67%, Fig.1) . Thus, the upstream GAA DNA methylation changes in both FRDA brain and heart are consistent with their proposed roles in inhibition of Another particularly interesting finding was the identification of differential DNA methylation at three specific CpG sites within the FXN promoter (sites 5, 7 and 8) and one CpG site within exon 1 (site 23) (Fig. 3A and B) . All of the other 55 CpG sites in the total of 59 CpG sites analysed show complete lack of DNA methylation, as to be expected for a CpG island that is situated at the start of a gene. CpG sites 5, 7 and 8 show incomplete methylation in the unaffected heart, but complete methylation in the FRDA heart (Fig. 3B) (Fig.4) . All of the 6 acetylated histone residues that we have examined show a GAA-induced gradient of comparative acetylation that is highest in the FXN promoter and lowest in the downstream GAA region. The single most altered histone residue is H3K9, which exhibits progressive (Fig. 4) . These changes concur with the previous findings of increased H3K9 di-and tri-methylation in the upstream GAA region of other cell types (23, 24) . However, we have now extended these studies to show that in FRDA brain the H3K9 di-and tri-methylation spreads to both FXN promoter and downstream GAA regions. and 56% in heart compared with Y47 (Fig. 5) . Thus, inhibition of FXN expression in transgenic mouse brain was not as severe as the 12% observed in the 750/650 GAA repeat-containing human FRDA brain ( Fig. 1 ), whereas levels of FXN expression in heart were more comparable. DNA methylation analysis was then performed on the single GAA repeat expansion-containing YG22 GAA shows an overall increase in DNA methylation, whereas the heart tissue shows an overall decrease in DNA methylation. Assessment of the entire mouse DNA repeat-induced decreases in histone H3 and H4 acetylation and increases in H3K9 methylation for both YG8 and YG22 transgenic mice (Fig. 7) , as we previously identified in human FRDA tissue (Fig. 4) . However, the level of deacetylation in the transgenic mouse tissue was not as great as that seen in the human tissue, possibly as a consequence of the smaller transgenic GAA repeat expansion sizes (190+90 for YG8 and 190 for YG22, compared with 750/650 for FRDA patient). Also, H4K16 acetylation is actually increased in all three FXN transgene regions of both YG8 and YG22 compared with Y47, which is different to the finding in human tissues. The greatest consistent histone residue changes that we found between the non-GAA (Y47) and both of the GAA (YG8 and YG22) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Thus, the hypermethylation detected in the FRDA upstream GAA region may be due to the GAA repeat mutation enhancing the effect of a putative methylation centre at the 5' end of the Alu sequence. At the same time, the addition of the We have additionally identified differential DNA methylation at four specific 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 shown to inhibit CpG methylation (38) . Furthermore, DNA demethylation has previously been shown to occur when there are few methylated CpG sites within a CpG island, but not when all of the CpG sites are methylated (39) , which is exactly the situation that we find for the FXN promoter region. However, the GAA Therefore, our combined data thus far indicate major roles for DNA methylation, histone H3K9 deacetylation and histone H3K9 methylation in the inhibition of FXN transcription in brain and heart tissues, with a less prominent role for deacetylation of other histone residues. The more severe epigenetic changes within the FXN intron 1 region compared with the promoter region support a hypothesis of transcription inhibition due to interference with elongation rather than initiation. Further work will be required to determine the exact relationships between DNA methylation, histone acetylation and methylation, heterochromatin 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 GAPDH control for the human samples as previously described (24) . For the analysis of transgenic mouse samples, the same three sets of FXN primers were used together with the following mouse Gapdh control primers: GapdhMF, 5'-TGACAAGAGGGCGAGCG-3' and GapdhMR, 5'-GGAAGCCGAAGTCAGGAAC-3'. Each tissue sample was subjected to two independent ChIP procedures, followed by triplicate quantitative PCR analysis. 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
MATERIALS AND METHODS
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